Navigation Links
Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
Date:10/25/2011

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies. The trial met its primary endpoint of statistically significant improvement in overall survival. This is the result of a pre-planned interim analysis conducted by an independent Data Monitoring Committee (DMC) of the CORRECT (Patients with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial. Per the recommendation of the DMC, the study has been unblinded and patients in the placebo arm will be offered treatment with regorafenib. In this trial, the safety and tolerability of regorafenib were generally as expected.  Data from the study are expected to be presented at a forthcoming scientific meeting.

Onyx recently entered into an agreement with Bayer under which Bayer will pay Onyx a royalty on any future global net sales of regorafenib in oncology.

"Patients with metastatic colorectal cancer are in need of new treatment options, and these data demonstrate that regorafenib increased overall survival," said Ted W. Love, M.D., Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals. "We look forward to seeing this promising therapy become available to patients as quickly as possible."

Bayer will continue discussions with health authorities worldwide, including the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA), regarding next steps in filing for approval of regorafenib in the treatment of mCRC.

About the CO
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)
2. Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases
3. Data From Phase 2 Clinical Studies of Telotristat Etiprate in Patients With Carcinoid Syndrome to be Presented at North American Neuroendocrine Tumor Society Meeting
4. DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
5. First Results From Ongoing Phase III Trial Show Malaria Vaccine Candidate, RTS,S* Reduces the Risk of Malaria by Half in African Children Aged 5 to 17 Months
6. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
7. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
8. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
9. Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
10. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
11. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... JERUSALEM , Feb. 27, 2015  Chiasma, Inc., ... lead product for the orphan condition acromegaly, today announced ... round. Participants in the financing included new investors Rock ... chip public investment fund, as well as existing investors ... and ARCH Venture Partners. Chiasma intends ...
(Date:2/26/2015)... DIEGO , Feb. 26, 2015  Tandem Diabetes ... device company and manufacturer of the t:slim® and t:flex™ ... public offering of 5,250,000 shares of its common stock ... share.  The net proceeds to Tandem from this offering ... discounts and commissions and other estimated offering expenses payable ...
(Date:2/26/2015)... , Feb. 26, 2015  Mobility Ventures LLC, ... agreement with Bank of America (NYSE: BAC ... to receive financing of the revolutionary MV-1 - - ... from the ground up to provide safe and comfortable ... can use their loan to purchase a new MV-1 ...
Breaking Medicine Technology:Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... 2011 Hospira, Inc. (NYSE: HSP ), a ... its board of directors has authorized the repurchase of up ... "This share repurchase program underscores our continued belief and optimism ... to return value to our shareholders," said F. Michael Ball, ...
... at the Fisher Center for Alzheimer,s Disease Research ... Greengard, Ph.D ., and Jennifer Warner-Schmidt, Ph.D., have ... and naproxen, reduce the effectiveness of the most ... serotonin reuptake inhibitors, or SSRIs, taken for depression ...
Cached Medicine Technology:Hospira Board Authorizes $1 Billion Share Repurchase Program 2Fisher Center Scientists Show That Anti-Inflammatory Drugs Reduce Effectiveness of SSRI Antidepressants 2Fisher Center Scientists Show That Anti-Inflammatory Drugs Reduce Effectiveness of SSRI Antidepressants 3
(Date:2/28/2015)... CA (PRWEB) February 28, 2015 ... of Central Coast area residents, recently announced a special ... System. It’s a treatment option for new and established ... off 2015 with a bright, white smile, Dr. Patel ... price of $299, marked down from the regular price ...
(Date:2/28/2015)... 2015 How would you describe ... There are all kinds of different leaders, each ... of the advantages and applications of different leadership ... a new product this spring called The Leadership ... connection between personality type, leadership, and success. The ...
(Date:2/28/2015)... 28, 2015 Developers of FCPX ... new overlay plugin for Final Cut Pro X entitled FCPX ... Overlay Chromatic gives users total control over 6k lens dirt ... of Pixel Film Studios. “FCPX Overlay Chromatic was professionally designed ... use interface.” , FCPX Overlay Chromatic Grunge 6K is a ...
(Date:2/28/2015)... 28, 2015 Memphis, TN: MedixSafe has ... for a new security reader named Guardian 2. ... is a new biometric scanner that significantly increases ... features, the new biometric scanner provides fast and ... , MedixSafe narcotics lockers with Vanguard ...
(Date:2/27/2015)... Hispanics develop alcoholic liver disease (ALD), a ... years earlier than Whites/Caucasians or African Americans, according to ... While previous research indicated that Hispanics tend to have ... -- published online in the journal Alcoholism: Clinical and ... to pinpoint racial and ethnic disparities in the ages ...
Breaking Medicine News(10 mins):Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2
... one in 800 people in the UK and causes chronic ... team found that a bacterium called Mycobacterium paratuberculosis releases a ... killing E.coli bacteria found in the body. E.coli is ... numbers. , It is thought that the Mycobacteria make ...
... Groups Select Intergy by Sage, TAMPA, Fla., Dec. ... to New Jersey -- have recently selected Intergy EHR,by ... to,representatives from each practice, the solution set provides essential,benefits ... recently signed onto Intergy EHR by Sage as their,Electronic ...
... CHICAGO, Dec. 10 Corbett Accel Healthcare ... veteran, to serve as its new,Executive Vice ... direct Corbett Accel,s business development strategy, lead ... units in conjunction,with the business unit leaders, ...
... InteGreat, a MED3OOO Company that,delivers EHR technology ... recently selected by Bright Medical Associates, of ... in all of their offices., Bright ... that serves over 125,000 patients annually throughout ...
... Mergers and,Acquisitions has just completed the transaction of ... VR Charlotte links business owners,across North Carolina to ... Established in 1965, Community Drugs pharmacist and ... Todd, the owner since 1975, has,built up Community ...
... Seasoned Healthcare Industry Executive Adds Depth to Management ... Inc.,(Nasdaq: EMAG ), a leader in enterprise ... networks, announced today that Chris,E. Perkins has been ... from a successful career at Per-Se Technologies,where he ...
Cached Medicine News:Health News:Scientists find how bacteria in cows' milk may cause Crohn's disease 2Health News:Pediatric Practices Select Intergy EHR by Sage for Electronic Health Records 2Health News:Pediatric Practices Select Intergy EHR by Sage for Electronic Health Records 3Health News:Pediatric Practices Select Intergy EHR by Sage for Electronic Health Records 4Health News:CORBETT ACCEL HEALTHCARE GROUP SELECTS ITS CMO: Veteran Brand Builder, Elisa Cooper-Broski, Will Lead Company's Marketing Initiatives 2Health News:Bright Medical Associates Selects InteGreat EHR for Ease of Use 2Health News:Bright Medical Associates Selects InteGreat EHR for Ease of Use 3Health News:Emageon Names Chris E. Perkins as Chief Operating Officer 2
The Bledsoe Ultimate CI is a sport functional knee brace designed for instabilities of combined ACL and PCL injured knees. Additional knee injuries to the medial collateral ligament along with the cr...
... best, the Bledsoe Extender Brace meets the physicians' ... to 86 cm) in length and up to ... easily fits patients from 5' (152 cm) to ... the patient progresses. The Bledsoe Extender is so ...
The Bledsoe Adjustable Knee Brace is designed to meet the most stringent demands of post-op care. When post-op care demands the best, the Bledsoe Adjustable Knee Brace is the physicians' preferred ch...
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Medicine Products: